CN105120859B - 治疗黑素瘤的方法 - Google Patents

治疗黑素瘤的方法 Download PDF

Info

Publication number
CN105120859B
CN105120859B CN201380075292.9A CN201380075292A CN105120859B CN 105120859 B CN105120859 B CN 105120859B CN 201380075292 A CN201380075292 A CN 201380075292A CN 105120859 B CN105120859 B CN 105120859B
Authority
CN
China
Prior art keywords
individual
melanoma
paclitaxel
albumin
braf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380075292.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN105120859A (zh
Inventor
N·P·德赛
M·雷恩施乐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
Abraxis Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/791,841 external-priority patent/US9149455B2/en
Application filed by Abraxis Bioscience LLC filed Critical Abraxis Bioscience LLC
Priority to CN201811025229.5A priority Critical patent/CN109200031A/zh
Publication of CN105120859A publication Critical patent/CN105120859A/zh
Application granted granted Critical
Publication of CN105120859B publication Critical patent/CN105120859B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
CN201380075292.9A 2013-02-11 2013-12-03 治疗黑素瘤的方法 Active CN105120859B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811025229.5A CN109200031A (zh) 2013-02-11 2013-12-03 治疗黑素瘤的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361763391P 2013-02-11 2013-02-11
US61/763,391 2013-02-11
US13/791,841 US9149455B2 (en) 2012-11-09 2013-03-08 Methods of treating melanoma
US13/791,841 2013-03-08
PCT/US2013/072877 WO2014123612A1 (en) 2013-02-11 2013-12-03 Methods of treating melanoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811025229.5A Division CN109200031A (zh) 2013-02-11 2013-12-03 治疗黑素瘤的方法

Publications (2)

Publication Number Publication Date
CN105120859A CN105120859A (zh) 2015-12-02
CN105120859B true CN105120859B (zh) 2018-10-09

Family

ID=51300036

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380075292.9A Active CN105120859B (zh) 2013-02-11 2013-12-03 治疗黑素瘤的方法
CN201811025229.5A Pending CN109200031A (zh) 2013-02-11 2013-12-03 治疗黑素瘤的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811025229.5A Pending CN109200031A (zh) 2013-02-11 2013-12-03 治疗黑素瘤的方法

Country Status (13)

Country Link
EP (1) EP2953622B1 (enExample)
JP (3) JP6388880B2 (enExample)
KR (1) KR102148551B1 (enExample)
CN (2) CN105120859B (enExample)
BR (1) BR112015019064A8 (enExample)
CA (1) CA2900668A1 (enExample)
ES (1) ES2872328T3 (enExample)
HK (1) HK1218506A1 (enExample)
IL (1) IL240388B (enExample)
MX (1) MX377729B (enExample)
NZ (1) NZ630239A (enExample)
WO (1) WO2014123612A1 (enExample)
ZA (1) ZA201505956B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2794147A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
KR101894689B1 (ko) 2010-03-29 2018-09-04 아브락시스 바이오사이언스, 엘엘씨 암의 치료 방법
WO2012154861A2 (en) 2011-05-09 2012-11-15 Mayo Foundation For Medical Education And Research Cancer treatments
EP3560486A1 (en) 2011-12-14 2019-10-30 Abraxis BioScience, LLC Use of polymeric excipients for lyophilization or freezing of particles
EP2903610B1 (en) 2012-10-01 2021-11-03 Mayo Foundation For Medical Education And Research Cancer treatments
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
CA2903454A1 (en) 2013-03-12 2014-10-02 Abraxis Bioscience, Llc Methods of treating lung cancer
EP2968191B1 (en) 2013-03-14 2021-06-16 Abraxis BioScience, LLC Methods of treating bladder cancer
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
WO2015195476A1 (en) 2014-06-16 2015-12-23 Mayo Foundation For Medical Education And Research Treating myelomas
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
ES2763318T3 (es) * 2014-10-06 2020-05-28 Mayo Found Medical Education & Res Composiciones de vehículo-anticuerpo y procedimientos para preparar y usar las mismas
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
EA036790B1 (ru) 2015-06-29 2020-12-22 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способ лечения злокачественной пекомы
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
WO2017031368A1 (en) * 2015-08-18 2017-02-23 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
US11571469B2 (en) 2016-01-07 2023-02-07 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
EP3413874A4 (en) 2016-02-12 2020-01-22 Mayo Foundation for Medical Education and Research TREATMENTS FOR BLOOD CANCER
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
AU2017238119A1 (en) 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
MX2019002474A (es) * 2016-09-01 2019-09-18 Mayo Found Medical Education & Res Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres.
JP2019526579A (ja) 2016-09-01 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｔ細胞癌を標的とする為の方法及び組成物
RU2019110071A (ru) 2016-09-06 2020-10-08 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Способы лечения злокачественных новообразований, экспрессирующих pd-l1
CN109890422A (zh) 2016-09-06 2019-06-14 梅约医学教育与研究基金会 紫杉醇-白蛋白-结合剂组合物及使用和制备该组合物的方法
WO2018048815A1 (en) 2016-09-06 2018-03-15 Nantibodyfc, Llc Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
WO2019070850A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. LOCAL ADMINISTRATION OF ANINEOPLASTIC PARTICLES IN COMBINATION WITH SYSTEMIC DELIVERY OF IMMUNOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
EP3768268A4 (en) 2018-03-20 2022-02-23 Abraxis BioScience, LLC METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE
EP4051241A4 (en) 2019-10-28 2023-12-06 Abraxis BioScience, LLC PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573108A (zh) * 2006-11-06 2009-11-04 阿布拉科斯生物科学有限公司 紫杉醇和白蛋白纳米颗粒联合贝伐单抗对抗癌症

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
SG166775A1 (en) 2005-02-18 2010-12-29 Abraxis Bioscience Llc Combinations and modes of administration of therapeutic agents and combination therapy
US8034765B2 (en) 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
JP2009538317A (ja) * 2006-05-26 2009-11-05 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
US20100166869A1 (en) 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
EP2367425B1 (en) * 2008-12-11 2018-02-28 Abraxis BioScience, LLC Combination therapy including a taxane and a further therapeutic agent
WO2012048223A1 (en) * 2010-10-08 2012-04-12 Abraxis Bioscience, Llc Sparc microenvironment signature, plasma sparc, and ldh as prognostic biomarkers in the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573108A (zh) * 2006-11-06 2009-11-04 阿布拉科斯生物科学有限公司 紫杉醇和白蛋白纳米颗粒联合贝伐单抗对抗癌症

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
E. Hersh et al..Society for melanoma research 2012 congress, Phase 3, randomized, open-label, multicenter trial of nab-paclitaxel (nab-P) vs dacarbazine (DTIC) in previously untreated patients with metastatic malignant melanoma (MMM).《 Pigment cell melanoma res.》.2012,第25卷第863页. *
Evan M. Hersh et al..A Phase 2 Clinical Trial of nab-Paclitaxel in Previously Treated and Chemotherapy-Naïve Patients With Metastatic Melanoma.《Cancer》.2009,第155-163页. *
Metastatic melanoma – a review of current and future drugs;Rodrigues Velho et al.;《Drugs in Context》;20121119;第1-17页 *
Society for melanoma research 2012 congress, Phase 3, randomized, open-label, multicenter trial of nab-paclitaxel (nab-P) vs dacarbazine (DTIC) in previously untreated patients with metastatic malignant melanoma (MMM);E. Hersh et al.;《 Pigment cell melanoma res.》;20121231;第25卷;第863页 *

Also Published As

Publication number Publication date
IL240388B (en) 2020-07-30
IL240388A0 (en) 2015-09-24
HK1218506A1 (zh) 2017-02-24
MX377729B (es) 2025-03-11
CN105120859A (zh) 2015-12-02
MX2015010312A (es) 2015-11-18
EP2953622A4 (en) 2016-09-21
JP2016513097A (ja) 2016-05-12
BR112015019064A8 (pt) 2019-11-12
EP2953622A1 (en) 2015-12-16
CN109200031A (zh) 2019-01-15
JP6470381B2 (ja) 2019-02-13
ES2872328T3 (es) 2021-11-02
CA2900668A1 (en) 2014-08-14
KR102148551B1 (ko) 2020-08-26
ZA201505956B (en) 2016-11-30
EP2953622B1 (en) 2021-03-24
JP2019056014A (ja) 2019-04-11
JP6388880B2 (ja) 2018-09-12
NZ630239A (en) 2017-08-25
WO2014123612A1 (en) 2014-08-14
JP2018016660A (ja) 2018-02-01
BR112015019064A2 (pt) 2017-07-18
KR20150119177A (ko) 2015-10-23

Similar Documents

Publication Publication Date Title
CN105120859B (zh) 治疗黑素瘤的方法
AU2018201814B2 (en) Methods of treating melanoma
JP6697017B2 (ja) 膵臓がんの処置方法
JP6257324B2 (ja) 膵臓がんの処置方法
KR20130109025A (ko) 방광암의 치료 방법
CN105007912A (zh) 白蛋白和紫杉醇的纳米颗粒组合物
HK40009403A (en) Methods of treating pancreatic cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant